Table 4.
Clinical studies investigating the role of multiple blood measurements in predicting cancer patient outcomes.
| Reference | Cancer type | Measurements | # of patients | Range cutoffs (survival) | Multivariate HR (OS) | Time of measurement |
|---|---|---|---|---|---|---|
| Aizawa et al. (103) | Gastric | NLR, CRP, Hb, Plt, Alb, lym, alb | 262 | NLR > 3.2, Hb < 13 g/dL, Plt > 250 K/µL, CRP > 1 mg/dL, alb < 35 g/L | ORs; Hb-1.89, p = 0.48; NLR—2.21, p = 0.012 | Baseline preoperative |
| Deng et al. (104) | Gastric | NLR, dNLR, PLR, LMR | 385 | NLR > 2.36, dNLR > 1.85, PLR > 132, LMR > 4.95 | All NS except dNLR—1.42, p = 0.012 | Preoperative |
| Guthrie et al. (1) | Colorectal | mGPS, NLR | 206 | mGPS,a NLR > 5 | mGPS—1.97, p < 0.05 NLR—3.07, p < 0.05 |
Preoperative |
| Hsueh et al. (105) | Laryngeal squamous cell cancer | NLR, PLR, LMR, plt, neut, lym, monocytes | NLR > 2.4, PLR > 111, LMR < 3.5, lym < 1.6 K/µL, neutr > 4.3 K/µL, plt > 200 K/µL | CSS: Lymph—2.20, p < 0.0001; NLR—1.84, p = 0.001, PLR—1.71, p = 0.002, LMR—1.98, p < 0.001 | Preoperative | |
| Jia et al. (106) | Breast | NLR, LMR | 1,570 | NLR < 2, LMR > 4.8 | NLR—1.63, p = 0.022 | Pretreatment |
| Kang et al. (107) | Non-small cell lung | NLR, PLR | 187 | NLR > 4, PLR > 160 | NLR—1.47, p = 0.043; PLR—NS | Pretreatment |
| Kim et al. (45) | Gastric | NLR, PLR | 1,986 | NLR > 2, PLR > 126 | NLR—1.4, p = 0.023 PLR—NS |
Presurgery |
| Kim et al. (108) | Ovarian clear cell carcinoma | NLR, PLR, LMR | 109 | NLR < 2.4, PLR < 178.3, MLR > 0.2, neut > 4.37 K/µL, plt > 300 K/µL, mono > 0.39 K/µL | All are NS in OS | Pretreatment |
| Kinoshita et al. (109) | Hepatocellular carcinoma | GPS, mGPS, NLR, PLR | 150 | GPS,b mGPS,a NLR > 5, PLRc | All NS except GPS—1.78, p = 0.002 | Pretreatment |
| Leitch et al. (110) | Colorectal | NLR, monocyte, mGPS | 149 | NLR > 5, mono > 0.9 K/µL, mGPSa | NLR-NS, monocyte—3.79, p = 0.015, mGPS—2.21, p = 0.024 | Presurgery |
| Martin et al. (111) | Advanced pancreatic | NLR, PLR, mGPS | 124 | NLR > 5, PLR > 200mGPSa | NLR—1.6, p = 0.02; PLR—1.58, p = 0.02; mGPS—1.41 p = 0.01 | During treatment |
| Oh et al. (112) | Heptocellular carcinoma | CRP, NLR | 318 | CRP > 6.3 mg/L, NLR > 2.3 | CRP—1.52, p = 0.027, NLR—1.60, p = 0.009 | Pretreatment |
| Stotz et al. (113) | Pancreatic | PLR, NLR, mGPS | 371 | PLR > 150, NLR > 5, mGPSa | PLR—NS, NLR—2.53, p < 0.001 (inoperable), NLR—1.61, p = 0.039 (operable), mGPS—NS | Pretreatment |
| Wang et al. (39) | Gastric | GPS, PLR, NLR, neut, plt, CRP, alb | 324 | GPS,b PLR,c NLR > 5, neut > 7.5 K/µL, plt > 400 K/µL, CRP > 10 mg/L, alb < 35 g/L | All-NS except GPS—1.40, p = 0.014 | Preoperative |
aMGPS = 1 if CRP > 10 mg/L, mGPS = 2 if CRP > 10 mg/L and alb < 35 g/L, mGPS = 0 if both CRP and alb are normal.
bGPS = 1 if CRP > 10 mg/L or alb < 35 g/L, GPS = 2 if CRP > 10 mg/L and alb < 35 g/L, GPS = 0 if both CRP and alb are normal.
cPLR = 1 if PLR > 150, PLR = 2 if PLR > 300, PLR = 0 if PLR < 150.
alb, albumin; CRP, C-reactive protein; plt, platelet; neut, neutrophil; lym, lymphocyte; mono, monocyte; OR, odds ratio; CSS, cancer-specific survival; Hb, hemoglobin; OS, overall survival; LMR, lymphocyte-to-monocyte ratio.